Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6 Mln
P/E Ratio
--
P/B Ratio
2.54
Industry P/E
--
Debt to Equity
--
ROE
-4.53 %
ROCE
-448.91 %
Div. Yield
0 %
Book Value
--
EPS
-6.58
CFO
$-74.28 Mln
EBITDA
$-339.64 Mln
Net Profit
$-578.48 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
GT Biopharma (GTBP)
| -23.87 | -7.12 | 0.52 | -37.07 | -68.39 | -49.60 | -73.05 |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
GT Biopharma (GTBP)
| -59.83 | -71.21 | -70.95 | -57.69 | 423.46 | -87.54 | -85.24 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 60.74 | 11,346.08 | 26.77 | 8.05 | |
| 62.57 | 6,566.51 | 50.6 | 23.56 | |
| 57.41 | 11,265.03 | 388.07 | 0.76 | |
| 7.64 | 9,024.30 | -- | -3.24 |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology... platform. The company develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 which targets B7-H3 on the surface of advanced solid tumors; GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. GT Biopharma, Inc. entered a master services agreement with Cytovance Biologics, Inc. to perform biologic development and manufacturing services, and to produce and test compounds; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California. Address: 315 Montgomery Street, San Francisco, CA, United States, 94104 Read more
Interim CEO & Executive Chairman
Mr. Michael Martin Breen
Interim CEO & Executive Chairman
Mr. Michael Martin Breen L.L.B.
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of GT Biopharma Inc (GTBP) stood at $ 4 Mln as on 31-Dec-24
The share price of GT Biopharma Inc (GTBP) is $2.32 (NASDAQ) as of 22-Apr-2025 11:16 EDT. GT Biopharma Inc (GTBP) has given a return of -68.39% in the last 3 years.
GT Biopharma Inc (GTBP) has a market capitalisation of $ 6 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of GT Biopharma Inc (GTBP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the GT Biopharma Inc (GTBP) and enter the required number of quantities and click on buy to purchase the shares of GT Biopharma Inc (GTBP).
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 which targets B7-H3 on the surface of advanced solid tumors; GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. GT Biopharma, Inc. entered a master services agreement with Cytovance Biologics, Inc. to perform biologic development and manufacturing services, and to produce and test compounds; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California. Address: 315 Montgomery Street, San Francisco, CA, United States, 94104
The CEO & director of Mr. Michael Martin Breen. is GT Biopharma Inc (GTBP), and CFO & Sr. VP is Mr. Michael Martin Breen L.L.B..
There is no promoter pledging in GT Biopharma Inc (GTBP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| GT Biopharma Inc. (GTBP) | Ratios |
|---|---|
|
Return on equity(%)
|
-453.39
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of GT Biopharma Inc (GTBP) was $0 Mln.
$0.15
(
